Bio-Techne (NASDAQ:TECH) Stock Acquired Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently bought shares of Bio-Techne Corp (NASDAQ:TECH). In a filing disclosed on January 05th, the Representative disclosed that they had bought between $1,001 and $15,000 in Bio-Techne stock on December 5th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 12/12/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 12/12/2025.
• Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 12/5/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 12/5/2025.
• Sold $1,001 – $15,000 in shares of CDW (NASDAQ:CDW) on 12/5/2025.
• Purchased $1,001 – $15,000 in shares of Clean Harbors (NYSE:CLH) on 12/3/2025.
• Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 12/2/2025.
• Purchased $1,001 – $15,000 in shares of Live Nation Entertainment (NYSE:LYV) on 12/2/2025.
• Sold $1,001 – $15,000 in shares of Teledyne Technologies (NYSE:TDY) on 12/2/2025.
• Purchased $1,001 – $15,000 in shares of Martin Marietta Materials (NYSE:MLM) on 12/2/2025.

Bio-Techne Trading Up 3.6%

NASDAQ TECH opened at $65.28 on Wednesday. The firm has a market capitalization of $10.17 billion, a PE ratio of 133.23, a P/E/G ratio of 4.34 and a beta of 1.47. The stock’s 50 day moving average is $60.42 and its 200 day moving average is $57.05. Bio-Techne Corp has a twelve month low of $46.01 and a twelve month high of $79.28. The company has a quick ratio of 2.81, a current ratio of 4.22 and a debt-to-equity ratio of 0.15.

Bio-Techne (NASDAQ:TECH) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.42 EPS for the quarter, meeting the consensus estimate of $0.42. The business had revenue of $286.56 million during the quarter, compared to analyst estimates of $292.02 million. Bio-Techne had a return on equity of 13.59% and a net margin of 6.41%.The company’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.42 earnings per share. Research analysts forecast that Bio-Techne Corp will post 1.67 earnings per share for the current fiscal year.

Bio-Techne Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 28th. Investors of record on Monday, November 17th were given a dividend of $0.08 per share. The ex-dividend date was Monday, November 17th. This represents a $0.32 annualized dividend and a dividend yield of 0.5%. Bio-Techne’s payout ratio is currently 65.31%.

Wall Street Analyst Weigh In

TECH has been the subject of a number of recent research reports. UBS Group lifted their price target on shares of Bio-Techne from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bio-Techne in a research note on Wednesday, October 8th. Wells Fargo & Company lifted their target price on shares of Bio-Techne from $59.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Cowen restated a “buy” rating on shares of Bio-Techne in a research note on Tuesday, October 14th. Finally, Argus raised their price objective on Bio-Techne from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Thursday, November 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $70.57.

Hedge Funds Weigh In On Bio-Techne

Hedge funds and other institutional investors have recently modified their holdings of the company. Oak Thistle LLC increased its position in Bio-Techne by 1.9% during the third quarter. Oak Thistle LLC now owns 9,314 shares of the biotechnology company’s stock valued at $518,000 after acquiring an additional 173 shares during the last quarter. Allworth Financial LP boosted its position in Bio-Techne by 28.4% in the third quarter. Allworth Financial LP now owns 786 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 174 shares during the last quarter. Angeles Wealth Management LLC grew its stake in shares of Bio-Techne by 3.4% during the 3rd quarter. Angeles Wealth Management LLC now owns 5,703 shares of the biotechnology company’s stock valued at $317,000 after purchasing an additional 189 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of Bio-Techne by 5.6% during the 3rd quarter. Exchange Traded Concepts LLC now owns 3,630 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 192 shares during the period. Finally, Farther Finance Advisors LLC increased its position in shares of Bio-Techne by 11.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,883 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 198 shares during the last quarter. 98.95% of the stock is owned by institutional investors.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.